The Hidden Dangers of Stopping Cholesterol-Lowering Meds

Patients with coronary artery disease who stop taking PCSK9 inhibitors may be putting themselves at risk. Researchers looked at 208 patients being treated with these medications. Over a median of 1,096 days, 94 patients stopped taking their prescribed treatment. Those who stopped experienced more major adverse cardiovascular events (MACE) compared to patients who continued their treatment.

The study found that the event curves started to diverge about three years after patients stopped taking the medication. This means that it took a few years for the increased risk to become apparent. Researchers used a statistical analysis to account for other factors that could influence the results. They found that stopping PCSK9 inhibitors was linked to a higher incidence of MACE.

PCSK9 inhibitors work by lowering levels of "bad" cholesterol in the blood. When patients stop taking these medications, their cholesterol levels may rise. This can increase the risk of heart attacks, strokes, and other cardiovascular events.

The findings highlight the importance of sticking to prescribed treatment plans. Patients with coronary artery disease should discuss any concerns about their medications with their healthcare providers. Stopping treatment without a valid reason may have serious consequences.

Understanding the risks and benefits of PCSK9 inhibitors can help patients make informed decisions about their care. These medications are just one part of a comprehensive treatment plan. Lifestyle changes, such as a healthy diet and regular exercise, also play a critical role in managing coronary artery disease.